
The Netherlands Authority for Consumers and Markets (ACM) has cleared the acquisition of the Dutch activities of veal company Van Dam by rival company Van Drie Group. Following an extensive investigation into the acquisition, ACM has determined that it is not likely that the acquisition will lead to lower purchase prices of calves or to foreclosure of competitors.
The Van Drie Group is active in the entire production chain in the veal sector. Van Drie’s main activities include the production of feed for calves, buying of young calves, calf husbandry, calf slaughterhouses, and the selling (export) of veal. The Van Drie Group is the market leader in the veal sector. Van Dam’s main activities include buying and selling calves, and calf husbandry.
ACM has assessed whether, after the acquisition, the leading market position of the Van Drie Group could result in a restriction of competition with adverse consequences. ACM has assessed whether, as a result of the acquisition, the Van Drie Group could lower the purchase prices it pays to dairy farmers and traders for their young calves. Lower prices can, particularly in the long term, lead to fewer investments in, for example, sustainability and animal welfare.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas